Sun Pharma Q4 Results: Net Profit Surges 26%, Revenue Rises on Robust Domestic Demand; Announces 500% Dividend

India's largest pharmaceutical company, Sun Pharmaceutical Industries, reported a healthy set of earnings for the fourth quarter of FY26, supported by steady growth in its domestic business and strong annual sales performance. The Mumbai-based drugmaker posted higher year-on-year profit and revenue growth, while also announcing a final dividend for shareholders.

Sun Pharma Q4 FY26 Results: Profit Rises 26% to Rs 2,714 Crore, Revenue Jumps

Sun Pharma reported a consolidated net profit of Rs 2,714.03 crore for the January-March quarter, marking a 26.24% increase compared with Rs 2,149.88 crore in the same period last year. Revenue from operations rose 12.8% year-on-year to Rs 14,611.79 crore, reflecting continued demand across key therapy segments and markets.

Despite the strong annual growth, the company's quarterly performance moderated compared with the previous quarter. Net profit declined from Rs 3,368.81 crore reported in Q3FY26, while revenue also slipped sequentially from Rs 15,520.54 crore. However, analysts generally view the yearly growth trend as a positive sign of stable business expansion.

500% Dividend! Sun Pharma Announces Final Dividend; Check Payout, Record Date

The company's board recommended a final dividend of Rs 5 per equity share of face value Re 1 for FY26. Earlier in the financial year, Sun Pharma had already paid an interim dividend of Rs 11 per share, taking the total dividend payout for FY26 to Rs 16 per share, unchanged from the previous year.

Sun Pharma Annual Results FY26: EBITDA Jumps 16%, Margins Improve to 30.3%

For the full financial year FY26, Sun Pharma posted a net profit of Rs 11,479.4 crore, registering 5% growth over the previous year. Annual sales increased 11.9% to Rs 58,220.1 crore, while EBITDA rose 16.1% to Rs 17,731.4 crore.

The company also reported an improvement in operating profitability for the full year, with EBITDA margin expanding to 30.3%, compared with 29% in FY25. This indicates better cost management and stronger contribution from high-margin businesses.

Sun Pharma's India Business Remains Key Growth Driver

The domestic formulations business continued to remain one of the strongest contributors to growth during the quarter. Sales from India formulations increased 14.8% in Q4FY26, driven by healthy demand in therapies such as cardiology, gastroenterology, central nervous system and orthopaedics.

For the full financial year, the India business contributed nearly 33% of Sun Pharma's consolidated sales after posting 14% annual growth.

Sun Pharma International Portfolio Shows Stable US Demand and Expanding Emerging Markets

Meanwhile, the company's US formulations business remained relatively stable. Revenue from the US market stood at 459 million dollars during the quarter and contributed 29% of overall FY26 consolidated sales.

Sun Pharma also saw encouraging traction in emerging markets, where revenue grew 13.6% during FY26 to reach 1.27 billion dollars, highlighting the company's expanding international presence.

Although quarterly EBITDA margin narrowed slightly to 27.1% from 28.7% a year ago, overall earnings growth and full-year performance reflected continued resilience in Sun Pharma's core business operations.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.